Quote | Immunome Inc. (NASDAQ:IMNM)
Last: | $17.18 |
---|---|
Change Percent: | 0.23% |
Open: | $17.34 |
Close: | $17.18 |
High: | $17.97 |
Low: | $17.15 |
Volume: | 852,654 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Immunome Inc. (NASDAQ:IMNM)
2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activat...
Message Board Posts | Immunome Inc. (NASDAQ:IMNM)
Subject | By | Source | When |
---|---|---|---|
Ha, sold in fall of 21 for $25. | wiwineguy | investorshub | 06/29/2023 1:42:46 PM |
$IMNM: Now 10.40 !!!!!!!!!!! | makinezmoney | investorshub | 06/29/2023 1:13:11 PM |
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50 | makinezmoney | investorshub | 06/29/2023 1:07:40 PM |
Immunome and Morphimmune Announce Definitive Merger Agreement and | Awl416 | investorshub | 06/29/2023 1:03:28 PM |
Good read | Major_Bankz | investorshub | 06/27/2023 4:07:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Immunome Inc. Company Name:
IMNM Stock Symbol:
NASDAQ Market:
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activat...
2024-04-01 09:00:06 ET David Nierengarten from Wedbush issued a price target of $33.00 for IMNM on 2024-04-01 07:59:00. The adjusted price target was set to $33.00. At the time of the announcement, IMNM was trading at $24.68. IMNM currently trades -20.38% versus its 52 w...
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on...